Retrospectively, a more comprehensive preoperative evaluation—including chest CT and serum VEGF-D—could have identified early-stage LAM and potentially allowed mTOR-inhibitor therapy to reduce AML volume, possibly obviating the need for immediate surgery [30, 31]. This evidence concerns the gene MTOR and acute myeloid leukemia.